The thought leaders in our community are good about sharing their thoughts on the issues of today. Here are the top read and shared guest posts of September that we think deserve sharing again.
Read More
By David Burda – No matter who I’m interviewing, no matter what the topic, and I ask them what the biggest obstacle or barrier to doing X is, their answer invariably is the CFO. That is, unless I’m interviewing the CFO. We need to be able to explain this to the CFO. We need to demonstrate the return on investment to the CFO.
By David Burda – The debate over private-equity ownership in healthcare really centers around two questions: Will prices for medical care go up or down after a PE firm buys a provider organization? Will quality and service go up or down after a PE firm buys a provider organization?
By David Burda – If you want great medical care, you should move to Lake Wobegon, where all the hospitals are above average. Anywhere else, chances are your medical care will be average. At least according to a short but revealing research letter published recently in JAMA Health Forum.
By David Burda – I’ve probably checked hundreds of boxes that said I read, accept and/or agree to a company’s privacy policy. Have I read any of the policies? Not a one. I’m taking a leap of faith that a company protects my personal information.
By David Burda – Hospitals, health systems and medical practices are businesses just like businesses in any other industry. They respond to economic incentives, and they do things for economic reasons. Plain and simple. Well, maybe not so plain and simple.
This month’s AI report includes news and updates from Gyant, Radiology Business, Harmony Healthcare IT, DrFirst, Insightin Health, Biogen, Happify Health, Intelerad Medical Systems, DiA Imaging Analysis, Vital, Fairtility, Exo, Henry Ford Health, Bayer, & more.
By David Burda – With a little extra effort, you always can find something revealing in surveys of healthcare executives, even when a multi-billion dollar, vertically integrated incumbent healthcare company sponsors the survey.
By David Burda – By now, we all know that hospitals’ level of compliance with the new price transparency rule would not be described as robust. It’s whatever the opposite of robust is. Feeble? Pathetic? Weak? There’s been a lot of speculation as to why even at this point, nearly 18 months after the rule went into effect.